BioNTech settles Covid-19 patent dispute with CureVac, P3
- Shidonna Raven
- 3 hours ago
- 1 min read
August 8, 2025
Source: The Guardian
Photo / Image Source: Unsplash,
The company, which has traditionally been a leader in vaccines, then signed a partnership with CureVac to catch up on mRNA technology and create its own Covid-19 jab. Last year, it fully licensed programmes from CureVac, including a Covid-19 vaccine and two flu vaccines in phase 2 trials, and a combination of Covid-19 and flu in phase 1. Since 2022, CureVac has been suing BioNTech, arguing that the rival had been “standing a bit on our shoulders” and infringed vital patents relating to mRNA technology. BioNTech and its partner Pfizer produced the first approved vaccines using the technology, generating billions of dollars in sales. But sales of the Covid-19 jab have been falling as take-up is now often limited to only the oldest and most vulnerable people.
How can such practices impact your health? How Why?
Share the wealth of health with your friends and family by sharing this article with 3 people today.
If this article was helpful to you, donate to the Shidonna Raven Garden and Cook E-Magazine Today. Thank you in advance.
Comments